Condition

Stage IV Renal Cell Cancer AJCC v8

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 18 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials18

Recruiting8

Common interventions25

Lead sponsors shown10

Clinical trials

18 shown

Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT StudyNCT07405086 · 2026-06-08

Imaging of Solid Tumors Using 18F-TRXNCT06942104 · 2025-07-03

Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) ProgramNCT06265285 · 2024-04-30

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic PlatformNCT06349642 · 2024-04-24

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or ThoraxNCT05092373 · 2022-04-29

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid TumorsNCT05269381 · 2022-03-31

Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME TrialNCT04693377 · 2021-03-16

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382 · 2019-05-13

Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO TrialNCT07576725 · 2026-12-01

NOT_YET_RECRUITING

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the BrainNCT06500455 · 2024-12-12

ACTIVE_NOT_RECRUITING

The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients With Advanced Solid Tumor Cancers Being Treated With Standard of Care Checkpoint InhibitorsNCT05967533 · 2023-06-02

Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVNCT04514484 · 2021-11-22

ACTIVE_NOT_RECRUITING

Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic RadiosurgeryNCT04588246 · 2021-08-05

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted AntibodiesNCT04902040 · 2021-04-14

18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain MetastasesNCT04752267 · 2021-02-15

DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell CancersNCT04388852 · 2020-08-20

ACTIVE_NOT_RECRUITING

Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported OutcomesNCT04501913 · 2019-12-24

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced MalignanciesNCT02419495 · 2015-06-26

Common interventions

Leading sponsors

M.D. Anderson Cancer Center 5 Mayo Clinic 3 National Cancer Institute (NCI) 2 NRG Oncology 2 City of Hope Medical Center 1 Fred Hutchinson Cancer Center 1 OHSU Knight Cancer Institute 1 Rahul Aggarwal 1 University of California, Davis 1 University of Southern California 1

Trial status mix

RECRUITING8

ACTIVE_NOT_RECRUITING3

TERMINATED3

COMPLETED2

NOT_YET_RECRUITING1

SUSPENDED1

Phase mix

PHASE18

PHASE25

PHASE32

EARLY_PHASE11

NA1

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.